Aqua Sphere Welcomes Three-Time World Champion Triathlete Mirinda Carfrae to the Team
Aqua Sphere, the premier swimming and triathlon equipment brand, today announced World Champion triathlete Mirinda “Rinny” Carfrae is joining the team as a global brand ambassador. As part of the Aqua Sphere team of athletes, Carfrae will train and compete utilizing the industry-leading Aqua Sphere range of products from training equipment to performance swimsuits and goggles.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200825005255/en/
Mirinda "Rinny" Carfrae joins premier swimming and triathlon equipment brand Aqua Sphere as a global brand ambassador. (Photo: Business Wire)
Carfrae, a three-time Ironman World Champion, will help grow the brand globally alongside her husband and fellow World Champion triathlete, Timothy O’Donnell. Carfrae and O’Donnell are part of Aqua Sphere’s growing roster of elite athletes that also includes World Champion Terenzo Bozzone, among others.
“I’m thrilled to be joining the Aqua Sphere team alongside my husband, Tim. I appreciate the long-term brand vision and I’m confident that Tim and I can make an immediate impact, especially as we embark on product designs heading into 2021,” said Carfrae. “Aqua Sphere has a significant global reach and their wide range of categories fit all our training and racing needs. The goggles fit great and have perfect clarity and I can’t wait to race in the gear once we start competitions again. Everyone we have worked with at Aqua Sphere shares an amazing passion for the brand and has welcomed us like family. And yes, the kid’s goggles are also Izzy approved.”
As a leader in the development of new and innovative swim products for athletes of all ages and abilities, Aqua Sphere has tapped Carfrae to endorse its entire product portfolio, including eye protection, swimwear, triathlon wetsuits and speedsuits, and swim fitness and training accessories. She will also contribute her unique perspective and insight to future product innovations.
“Rinny is a world class athlete who is dedicated to her sport and her family, and we are fortunate to have her join our team at Aqua Sphere,” said Andrew Gritzbaugh, General Manager of Aqua Lung, the parent company of Aqua Sphere. “As one of the world’s most decorated female triathletes, her experience, insights and talent are welcomed assets to the Aqua Sphere brand as we continue to solidify our category leadership position in the triathlon space.”
Originally from Australia, and now residing in Boulder, Colo., Carfrae is one of the world’s most successful triathletes. She has won three Ironman World Championships in 2010, 2013, and 2014 and her run course record from 2014 still stands today (2:50:26). With over 50 wins at major events throughout the world and seven podium performances at Kona in the span of a decade, Carfrae is recognized as one the of the greatest triathletes of all time.
Carfrae is currently gearing up to compete at Ironman World Championships – Kona in 2021.
About AQUA SPHERE
Established in Genoa, Italy, in 1998, Aqua Sphere is the premier swimming and triathlon equipment brand. With the launch of its cutting-edge Seal Mask—the world’s first swim mask, the company set the industry standard and today continues to innovate with a complete range of premium products, including eye protection, swimwear, triathlon wetsuits, speedsuits, swim fitness and training accessories. The designs have gained the respect and loyal following of many celebrities and notable athletes, including the world’s most decorated Olympian Michael Phelps, with whom Aqua Sphere has launched Phelps, a global brand of performance swimwear. Alongside its parent company Aqua Lung and supported by an international distribution network, Aqua Sphere has grown into a worldwide enterprise representing unparalleled design, development and manufacturing expertise, with a global footprint in more than 60 countries. For more information, visit: www.AquaSphereSwim.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200825005255/en/
Contact information
Lindsay Goodson
lgoodson@aqualung.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress18.9.2020 13:55:00 EEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial of mobocertinib (TAK-788), demonstrating mobocertinib achieved a duration of response (DoR) of more than one year in the trial’s study population of patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC). “We’re pleased to present our ongoing research in lung cancer at this year’s virtual ESMO congress, including new
Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal18.9.2020 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced results from its Phase 2 POD1UM-202 trial evaluating retifanlimab, a PD-1 inhibitor, in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed following standard platinum-based chemotherapy. The trial enrolled 94 patients, including those with well-controlled human immunodeficiency virus (HIV) infection (10%). Retifanlimab monotherapy resulted in a confirmed objective response rate (ORR) of 14% as determined by independent central review (ICR) using RECIST v1.1. Responses were observed regardless of PD-L1 status, presence of liver metastases, age or HIV+ status. Retifanlimab was generally well-tolerated with a safety profile as expected of a PD-1 inhibitor and no loss of HIV infection control. Key findings from POD1UM-202: N=94 ORR* (95% CI) 13.8% (7.6-22.5) Best OR*, n 1 CR 12 PR 33 SD DCR 48.9% DOR, median (95% CI), months 9.5 (5.6-NE) PFS, median (95% CI), months 2.3 (1.9-3.6) OS, median (95
Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure18.9.2020 10:30:00 EEST | Press release
Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200918005116/en/ Cube Infrastructure Managers, the European infrastructu
Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 09:00:00 EEST | Press release
Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price
ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months18.9.2020 08:00:00 EEST | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the release of first efficacy and safety data from the CLARINET FORTE study, with the abstract to be presented as a mini-oral presentation at the 2020 European Society for Medical Oncology (ESMO) Congress, taking place virtually from 19-21 September 2020. The prospective single-arm, open-label, exploratory, international Phase II study investigated the efficacy and safety of increasing the dose frequency of Somatuline® Autogel ® (lanreotide) in patients with pancreatic or midgut NETs with centrally-assessed progression within the last two years while on a standard lanreotide regimen for ≥24 weeks. An extension of progression-free survival (PFS) rates and encouraging disease-control rates (DCR) were recorded in both tumor types, with no new safety signals. “These results support a clinically meaningful benefit to a population of patients with high unmet medical need by potentially delaying escalation to more toxic treatm
Vifor Pharma Group Announces Successful Sale of OM Pharma18.9.2020 08:00:00 EEST | Press release
Regulatory News: Vifor Pharma has today announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding Ltd. The terms of the deal include: A purchase consideration of MCHF 435 for 100% of the share capital An earn out related to potential future value gains on 20% of Optimus Holding Ltd. equity to be determined before the end of 2027 upon a trade sale, IPO or EBITDA multiple This earn out together with the purchase consideration could result in a total transaction value exceeding MCHF 500. The deal is expected to close within 30 days. OM Pharma is a Geneva-based company mainly active in the field of microbial derived immunotherapeutics and has developed strongly outside the core strategy of Vifor Pharma over the past few years. Optimus Holding Ltd. is a Swiss Group, founded by Etienne Jornod together with long-standing Swiss entrepreneurs and Abdi Ibrahim (28.5%), a Turkey-based pharmaceutical company operating in 12 countries a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom